UTHR Q1 2025 Earnings
Reported Apr 30, 2025 at 6:33 AM ET · SEC Source
Q1 25 EPS
$6.63
BEAT +5.62%
Est. $6.28
Q1 25 Revenue
$794.4M
BEAT +9.37%
Est. $726.4M
vs S&P Since Q1 25
+60.2%
BEATING MARKET
UTHR +90.2% vs S&P +30.0%
Market Reaction
Did UTHR Beat Earnings? Q1 2025 Results
United Therapeutics opened 2025 with a record-breaking first quarter, posting revenue of $794.40 million, a 17.2% year-over-year gain that cleared the $726.36 million consensus estimate by 9.37%, while diluted EPS of $6.63 topped the $6.28 analyst fo… Read more United Therapeutics opened 2025 with a record-breaking first quarter, posting revenue of $794.40 million, a 17.2% year-over-year gain that cleared the $726.36 million consensus estimate by 9.37%, while diluted EPS of $6.63 topped the $6.28 analyst forecast by 5.62%. The standout driver behind the beat was the Tyvaso franchise, which generated $466.30 million in total revenue, a 25% surge fueled by Tyvaso DPI's 33% jump to $302.50 million as more patients, including those with pulmonary hypertension associated with interstitial lung disease, benefited from improved Medicare Part D coverage under the Inflation Reduction Act. Orenitram and Remodulin added further momentum, growing 14% and 8% respectively. The company's balance sheet remained a pillar of strength, with $5.03 billion in cash and investments against modest total liabilities of $936.70 million. Looking ahead, management pointed to several pipeline catalysts, including the TETON 2 readout in idiopathic pulmonary fibrosis and planned first-in-human studies for its xenotransplantation organ programs, as reasons for continued confidence through the remainder of 2025.
Key Takeaways
- • Tyvaso DPI volume growth driven by continued patient uptake, including PH associated with interstitial lung disease
- • Medicare Part D benefit redesign under the Inflation Reduction Act boosted Tyvaso DPI and Orenitram commercial utilization
- • U.S. Remodulin volume increases
- • Orenitram volume growth and price increases
- • International nebulized Tyvaso revenue growth from distributor order timing
UTHR YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
UTHR Revenue by Segment
With YoY comparisons, source: SEC Filings
UTHR Revenue by Geography
With YoY comparisons, source: SEC Filings
“2025 is off to a tremendous start as we reported yet another quarter of record revenue. Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout of TETON 2 in idiopathic pulmonary fibrosis and the planned commencement of our UKidney first in human clinical study, respectively. Moreover, we're excited to advance our multiple shots on goal approach to creating an unlimited supply of transplantable organ alternatives with anticipated filings of investigational new drug applications with the FDA for our UHeart and UThymoKidney products.”
— Martine Rothblatt, Q1 2025 Earnings Press Release
UTHR Earnings Trends
UTHR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
UTHR EPS Trend
Earnings per share: estimate vs actual
UTHR Revenue Trend
Quarterly revenue: estimate vs actual
UTHR Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 BEAT FY | $7.10 | $7.70 | +8.45% | $790.2M | -2.18% |
| FY Full Year | $26.95 | $27.86 | +3.39% | $3.18B | -0.55% |
| Q3 25 BEAT | $6.96 | $7.16 | +2.86% | $799.5M | -1.65% |
| Q2 25 MISS | $6.92 | $6.41 | -7.31% | $798.6M | -0.63% |
| Q1 25 BEAT | $6.28 | $6.63 | +5.62% | $794.4M | +9.37% |